News & Perspective

Mar 31, 2011

Mar 31, 2011

US awards contract for long-acting flu antiviral

(CIDRAP News) – The US government today announced the award of a $231 million, 5-year contract to an Australian company for advanced development of a single-dose, long-acting influenza drug in the neuraminidase inhibitor class.

The contract was awarded to Biota Scientific Management Pty, Ltd., of Melbourne, according to the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services.

Feb 17, 2011

Feb 17, 2011

WHO sticks with current strains for next flu vaccine

(CIDRAP News) – Signaling that the current flu strains are likely to persist over the next several months, the World Health Organization (WHO) today recommended sticking with the current trio of vaccine strains for the Northern Hemisphere's next influenza season.

The WHO's vaccine strain advisory committee met on Feb 15 and 16 and released its recommendation on the WHO's Web site. The group recommends the following for next season's vaccine:

Jan 18, 2011

Jan 18, 2011

Northern Hemisphere countries show steady rise in flu

(CIDRAP News) – Flu activity is increasing in many of the Northern Hemisphere's temperate-zone countries, with influenza B cocirculating with the 2009 pandemic H1N1 virus across Europe and teaming up with influenza A (H3N2) in the United States and Canada, the World Health Organization (WHO) said in its latest update.

Oct 06, 2010

Oct 06, 2010

Expert pair airs lessons learned from global flu response

(CIDRAP News) – Two internationally known health officials yesterday gave their assessment of the global response to the 2009 H1N1 pandemic, saying good decisions were made based on what was known early in the outbreak but adding that the experience yielded several important lessons, such as the need for more flexible pandemic plans and the need to communicate more clearly about risks.

Sep 10, 2010

Sep 10, 2010

Japan approves second new flu antiviral this year

(CIDRAP News) – Japan today approved a new long-acting influenza antiviral drug, Inavir (laninamivir), made by Daiichi Sankyo Co. Ltd., marking the second new flu drug licensed there this year.

Pages

by Topic

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»